Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations (2016 - 2026)

Aytu Biopharma has reported Income from Continuing Operations over the past 15 years, most recently at 10584000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 1691.58% to 10584000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24559000.0 through Dec 2025, down 528.27% year-over-year, with the annual reading at 14182000.0 for FY2025, 13.27% down from the prior year.
  • Income from Continuing Operations was 10584000.0 for Q4 2025 at Aytu Biopharma, down from 1965000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 3940000.0 in Q1 2025 and troughed at 53291000.0 in Q1 2022.
  • The 5-year median for Income from Continuing Operations is 6693000.0 (2022), against an average of 9481789.47.
  • The largest YoY upside for Income from Continuing Operations was 272.2% in 2025 against a maximum downside of 1691.58% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 11548000.0 in 2021, then soared by 42.04% to 6693000.0 in 2022, then surged by 108.95% to 599000.0 in 2023, then rose by 11.02% to 665000.0 in 2024, then crashed by 1691.58% to 10584000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Income from Continuing Operations are 10584000.0 (Q4 2025), 1965000.0 (Q3 2025), and 19880000.0 (Q2 2025).